Lipocine Reports LPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients with Cirrhosis By…
Lipocine (LPCN) Reports LPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients with Cirrhosis
Lipocine Inc. (NASDAQ:), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its…